Sanofi
SNY
707 hedge funds and large institutions have $12.7B invested in Sanofi in 2023 Q4 according to their latest regulatory filings, with 99 funds opening new positions, 197 increasing their positions, 290 reducing their positions, and 74 closing their positions.
34% more first-time investments, than exits
New positions opened: 99 | Existing positions closed: 74
2% more funds holding
Funds holding: 696 → 707 (+11)
9% more call options, than puts
Call options by funds: $97.5M | Put options by funds: $89.6M
0.26% more ownership
Funds ownership: 19.91% → 20.17% (+0.26%)
6% less capital invested
Capital invested by funds: $13.5B → $12.7B (-$811M)
27% less funds holding in top 10
Funds holding in top 10: 11 → 8 (-3)
32% less repeat investments, than reductions
Existing positions increased: 197 | Existing positions reduced: 290
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$411M |
| 2 |
MIP
Mondrian Investment Partners
London,
United Kingdom
|
+$76.6M |
| 3 |
AC
Armistice Capital
New York
|
+$50.7M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$37.5M |
| 5 |
MIS
Morningstar Investment Services
Chicago,
Illinois
|
+$36.3M |
Top Sellers
SNY Hedge Fund Activity: Q4 2023 in Review
707 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Sanofi (SNY) for Q4 2023, worth a combined $12.7B — down 6% from $13.5B a quarter earlier.
Buyers outnumbered sellers: 99 funds opened new SNY positions and 74 closed out — a net gain of 25 holders — while 197 added to existing stakes and 290 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $411M. The largest seller was Camber Capital Management, exiting entirely with an estimated $148M sold.
- 707 institutional investors held Sanofi (SNY) as of Q4 2023, up from 696 in Q3 2023.
- Funds reported $12.7B of Sanofi stock for Q4 2023, down 6% quarter-over-quarter.
- 99 funds opened new Sanofi positions in Q4 2023 and 74 closed out, a net change of +25 holders.
- The largest Sanofi buyer in Q4 2023 was Morgan Stanley, an estimated $411M added.
- The largest Sanofi seller in Q4 2023 was Camber Capital Management, an estimated $148M sold.
Based on aggregated 13F filings for Q4 2023.